Loratadine a second-generation antihistamine was FDA approved in 1993 and off -patent in 2002 when it became available over the counter. It acts by blocking the H1 histamine receptor.
It is a catatonic amphiphilic drug (CAT), which enters the ascitic lysosome. It is then trapped and accumulated 1000 full. This then interrupts lysosomal function and serves as an autophagy inhibitor. This makes the cancer cell more fragile and will induce “lysosomal cell death “. It has also been shown to be synergistic with chemotherapy.
In 2016 Dr. Ellegaard et al. screened a library of 72 CAD drugs for activity against non-small cell lung cancer. They found that the use of this was associated with reduce mortality among patients with non-localized cancer. In addition to these antihistamines help reverse multidrug resistant.
In 2019 Dr. Masana et al. was searching for a drug to revert the gene signature in leukemia cell lines and found that these antihistamines reversed a transformation of the gene signature. “When studied in vitro and in vivo mouse xenograft, these antihistamines selectively killed leukemia cells while sparing normal cells.
Re-purposed cancer drugs should always be used in combination to promote synergy. Every attempt should be made to block glycolysis, block oxidative phosphorylation as well as block autophagy.
If you are interested in re-purposed cancer drugs, circulating cancer stem cell evaluation, low-dose metronomic genomic chemotherapy, natural substances, and cancer vaccines we can help.
Please call us at 480-361-7020.